医学
利拉鲁肽
2型糖尿病
糖尿病
儿科
内分泌学
作者
William V. Tamborlane,Margarita Barrientos‐Pérez,Udi Fainberg,Helle Frimer‐Larsen,Mona Hafez,Paula M. Hale,Muhammad Yazid Jalaludin,М. А. Коваренко,Ingrid Libman,Jane Lynch,Paturi Rao,Naim Shehadeh,Serap Turan,Daniel Weghuber,Timothy Barrett
标识
DOI:10.1056/nejmoa1903822
摘要
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI